SHENYANG XINGQI PHARMACEUTICAL CO.(SZ:300573) Zhi Tong Cai Jing·2025-10-09 08:33Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-129 vitreous sustained-release injection, a modified new drug aimed at treating diabetic macular edema and macular edema caused by retinal vein occlusion [1] Group 1: Product Development - SQ-129 vitreous sustained-release injection is classified as a chemical drug type 2.2 modified new drug [1] - The clinical application is intended for (1) treatment of diabetic macular edema (DME) in adult patients; (2) treatment of macular edema caused by branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in adult patients [1] - The company has completed various studies, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value for SQ-129 [1] Group 2: Market Context - Currently, there are no approved products in the domestic and international markets for SQ-129 [1]